Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.21.2
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2021
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

The Company has the following marketed products, Qbrexza®, Accutane®, Targadox®, Ximino®, Exelderm®, Luxamend® and Ceracade®. Substantially all of the Company’s product revenues are recorded in the U.S. Revenues by product are summarized as follows (dollars in thousands):

    

Three months ended September 30, 

    

Nine Months Ended September 30, 

    

2021

    

2020

    

2021

    

2020

Revenue

  

  

  

  

Targadox®

$

5,184

$

7,214

$

18,110

$

22,195

Ximino®

 

2,864

 

1,031

 

6,277

 

5,854

Exelderm®

 

1,366

 

1,226

 

4,319

 

2,913

Accutane®

 

3,531

 

 

5,672

 

Qbrexa®

 

6,636

 

 

11,204

 

Other branded revenue

 

29

 

(24)

 

35

 

(154)

Total Product revenue, net

$

19,610

$

9,447

$

45,617

$

30,808